Prostate Cancer

By: Gaudencio Olgin, MD Robotic and Minimally Invasive Urologic Surgeon Robotics Program Medical Director at DHR Health Prostate cancer is the second most common cancer among men, affecting 1 in 9 men in their lifetime, and the second leading cause of cancer death in men after lung cancer. As a man ages, his chances of being diagnosed with prostate cancer increases. Men at an increased risk are African-American or have a first degree relative (father, brother, son) who has been diagnosed with this malignancy. The prostate is a golf ball sized gland found only in men that is located underneath the bladder and in front of the rectum. It surrounds the urine tube that carries urine from the bladder to and through the penis. Since prostate growth is a natural process of aging, men may experience urinary symptoms such as weakened urinary flow and more frequent trips to the bathroom. These types of symptoms may also be seen in prostate cancer. In general, there are NO signs specific t...

Sponsored Content by the Janssen Pharmaceutical Companies of Johnson & Johnson Introduction Patients with prostate cancer and their families must process complex information and work with their healthcare providers to make significant decisions along their journey. 1 Navigators play a key role in helping patients manage the challenges of the prostate cancer care treatment continuum, which can at times be overwhelming or frightening. 2 Patients come to rely on these professionals as their translators, educators, and advocates. As a step toward defining best practices for prostate cancer navigators, Janssen Biotech, Inc., and the Academy of Oncology Nurse & Patient Navigators (AONN) convened a virtual roundtable of navigators who play key roles in oncology or urology settings across the country. The panelists, moderated by Emily Gentry, BSN, RN, Senior Director of Education and Program Development at AONN, included three major categories of oncology navigators: Oncology ...

better-informedIn support of National Prostate Cancer Awareness Month, the CURE® Speaking Out video series has revealed a five-episode discussion titled, "Discussing Trends in Prostate Cancer," featuring Charles J. Ryan, M.D., professor of medicine and director of the division of hematology, oncology and transplantation at the University of Minnesota. Ryan is a member of the ZERO - The End of Prostate Cancer medical advisory board. “We are honored to have Dr. Charles Ryan partake in our educational series to increase awareness of and help prevent prostate cancer,” said Mike Hennessy Jr., president, and CEO of MJH Life Sciences™, parent company of CURE Media Group. “These expert video clips are an incredible resource, and we encourage our viewers and readers to share with patients, caregivers and survivors.” During this series, Ryan discusses a variety of topics related to prostate cancer. In the first episode, he provides an overview of the basics of the disease, includi...

DUBLIN , Aug. 27, 2020 /PRNewswire/ -- The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. The "US Prostate Cancer Market and Competitive Landscape Highlights - 2020" report provides comprehensive insights into Prostate Cancer pipeline products, Prostate Cancer epidemiology, Prostate Cancer market valuations and forecast, Prostate Cancer drugs sales and competitive landscape in the US. The research is classified into seven sections - Prostate Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares. Research Scope: Prostate Cancer pipeline: Find out the products in clinical trials for the treatment of Prostate Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products Prostate Cancer epidemiology: Find out th...

Latest released the research study on  Global Hormone Refractory Prostate Cancer Market, offers a detailed overview of the factors influencing the global business scope. Hormone Refractory Prostate Cancer Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Hormone Refractory Prostate Cancer Market. The study covers emerging player’s data, including: competitive landscape, sales, revenue and global market share of top manufacturers. Top players in Global Hormone Refractory Prostate Cancer Market are: AbbVie Inc. (United States) Acceleron Pharma Inc. (United States) AB Science SA (France) AstraZeneca Plc. (United Kingdom) Astellas Pharma Inc. (Japan) Boston Biomedical, Inc. (United States) Dendreon Corporation (United States) Sanofi S.A (France) Johnson & Johnson (Unit...

Dublin, Aug. 25, 2020 (GLOBE NEWSWIRE) -- The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. Prostate Cancer pipeline: Find out the products in clinical trials for the treatment of Prostate Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products Prostate Cancer epidemiology: Find out the number of patients diagnosed (prevalence) with Prostate Cancer in the US Prostate Cancer drugs: Identify key products marketed and prescribed for Prostate Cancer in the US, including trade name, molecule name, and company Prostate Cancer drugs sales: Find out the sales revenues of Prostate Cancer drugs in the US Prostate Cancer market valuations: Find out the market size for Prostate Cancer drugs in 2019 in the US. Find out how the market advanced from 2016 and forecast to 2025 Prostate Cancer drugs market share: Find out the market shares for key Prostate...

The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. The "US Prostate Cancer Market and Competitive Landscape Highlights - 2020" report provides comprehensive insights into Prostate Cancer pipeline products, Prostate Cancer epidemiology, Prostate Cancer market valuations and forecast, Prostate Cancer drugs sales and competitive landscape in the US. The research is classified into seven sections - Prostate Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares. Research Scope: Prostate Cancer pipeline: Find out the products in clinical trials for the treatment of Prostate Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products Prostate Cancer epidemiology: Find out the number of patients diagnosed (prevalence)...

DUBLIN--( BUSINESS WIRE )--The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. The "US Prostate Cancer Market and Competitive Landscape Highlights - 2020" report provides comprehensive insights into Prostate Cancer pipeline products, Prostate Cancer epidemiology, Prostate Cancer market valuations and forecast, Prostate Cancer drugs sales and competitive landscape in the US. The research is classified into seven sections - Prostate Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares. Research Scope: Prostate Cancer pipeline: Find out the products in clinical trials for the treatment of Prostate Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products Prostate Cancer epidemiology: Find out the number of pati...

The first patient has been randomized in the phase 3 ESCALATE trial, which is evaluating combination therapy with the radiopharmaceutical radium 223 dichloride (Xofigo) plus either enzalutamide (Xtandi) or darolutamide (Nubeqa) in patients with metastatic castration-resistant prostate cancer (mCRPC). 1,2 The study is specifically comparing the radium-223 combination with a control arm of patients who will receive placebo plus enzalutamide or darolutamide. The targeted enrollment is 500 patients and the primary outcome measure is symptomatic skeletal event-free survival (SSE-FS). "The eventual outcome analytics may potentially enhance treatment options for mCRPC as patients as well as augment our understanding of advanced prostate cancer sequencing strategies. We are honored to have enrolled and randomized the first subject and are very appreciative of our trial site organization's ongoing commitment," Neal Shore, MD, of Carolina Urologic Research Center, the principal ...

The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen receptor works in cancer, researchers at Baylor College of Medicine conducted comprehensive studies of the 3-D structure of the receptor. The findings unveiled the structure of a site on the receptor that seems to be at the heart of its action, called the N-terminal domain, where it interacts with activity-enhancing coactivators that together regulate gene expression that drives prostate cancer. The study, published in the journal Molecular Cell , offers new insights for the design of future treatments for this devastating condition. The androgen receptor "The androgen receptor binds to and mediates the effects of the androgenic hormone testosterone. The receptor is found in several tissues of both males and females, including skeletal muscle, heart and the nervous and the reproductive...

The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen receptor works in cancer, researchers at Baylor College of Medicine conducted comprehensive studies of the 3-D structure of the receptor. The findings unveiled the structure of a site on the receptor that seems to be at the heart of its action, called the N-terminal domain, where it interacts with activity-enhancing coactivators that together regulate gene expression that drives prostate cancer. The study, published in the journal Molecular Cell , offers new insights for the design of future treatments for this devastating condition. The androgen receptor “The androgen receptor binds to and mediates the effects of the androgenic hormone testosterone. The receptor is found in several tissues of both males and females, including skeletal muscle, heart and the nervous and the reproductive syste...

The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen receptor works in cancer, researchers at Baylor College of Medicine conducted comprehensive studies of the 3-D structure of the receptor. The findings unveiled the structure of a site on the receptor that seems to be at the heart of its action, called the N-terminal domain, where it interacts with activity-enhancing coactivators that together regulate gene expression that drives prostate cancer. The study, published in the journal Molecular Cell , offers new insights for the design of future treatments for this devastating condition. The androgen receptor "The androgen receptor binds to and mediates the effects of the androgenic hormone testosterone. The receptor is found in several tissues of both males and females, including skeletal muscle, heart and the nervous and the reproductive ...

Read the Full Video Transcript Lecture Presentation: Neal Shore : Hello, and welcome to our program today. This is one of a series of modules and the title, subject of our series of really educational events is called "Precision Medicine, PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Educational Forum". Really pleased today to have an outstanding faculty. Dr. Oliver Sartor, who is going to discuss academic practice perspectives on integrating PSMA lutetium-177 into clinical practice, lessons learned from radium-223 and more. Dr. Sartor is a Professor of Medical Oncology at Tulane. And then we'll have Nick Vogelzang, who is an internationally renowned expert also in prostate cancer, who will talk about the lessons learned in going from radium-223 and other radiopharmaceuticals into this newer age of radiolagand conjugates, and how it might impact a community medical oncology practice. And we're really fortunate to have Alicia Morgans, medical on...

SHORT information videos are breaking down healthcare barriers across the wider Grampians region for Ballarat Health Services' prostate care specialists. BHS aims to try and inform general practitioners about the latest in prostate cancer treatment options in a face-to-face forum to better promote smoother collaboration for patients. Like all healthcare, prostate care services have had to adapt in getting the right information to clinicians and patients amid COVID-19 pandemic restrictions. Ballarat-based prostate care nurse Gay Corbett said a suite of raw region-focused informative videos for GPs was actually reaching further across Ballarat and into the region with doctors able to review content when it suited them best, find relevant parts to share with patients and friendly faces in the videos helped too. "Seeing faces of local clinicians has meant they can show patients as well - this is who you might see - and gives ideas for people about what it's going to be like,...